Quarterly Results

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1087.10-27.8 (-2.49 %)
PREV CLOSE ( ) 1114.90
OPEN PRICE ( ) 1100.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 75136
TODAY'S LOW / HIGH ( )1079.00 1104.20
52 WK LOW / HIGH ( )574.8 1177
NSE1087.05-27.45 (-2.46 %)
PREV CLOSE( ) 1114.50
OPEN PRICE ( ) 1109.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1087.05 (1075)
VOLUME 1304443
TODAY'S LOW / HIGH( ) 1079.00 1109.00
52 WK LOW / HIGH ( )575.35 1177.1
Quarters
Select year  
( in Million)
Particulars
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Audited / UnAudited
UnAudited
UnAudited
UnAudited
Audited
Net Sales
73517.8
72194.2
68505.2
64729.6
Total Expenditure
57504.7
58459.8
56991.5
54707.8
PBIDT (Excl OI)
16013.1
13734.4
11513.7
10021.8
Other Income
1625.2
1869.8
1163.3
1349.1
Operating Profit
17638.3
15604.2
12677
11370.9
Interest
755.5
681.8
565.5
556
Exceptional Items
NA
NA
-697.5
NA
PBDT
16882.8
14922.4
11414
10814.9
Depreciation
4232.7
4175
3265.6
3455.7
Profit Before Tax
12650.1
10747.4
8148.40
7359.19
Tax
3224.5
3237
2423.2
2241.5
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
9425.6
7510.40
5725.20
5117.69
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
9425.6
7510.40
5725.20
5117.69
Minority Interest
-36.8
52.4
10.4
3.6
Shares of Associates
-25.9
9
-28.1
-58.6
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
9362.9
7571.8
5707.5
5062.7
Equity Capital
585.9
585.9
585.9
585.9
Face Value (IN RS)
1
1
1
1
Reserves
NA
NA
NA
NA
Calculated EPS
15.98
12.92
9.74
8.64
Calculated EPS (Annualised)
63.92
51.69
38.96
34.56
No of Public Share Holdings
282223138
282223138
282223138
282223138
% of Public Share Holdings
48.17
48.17
48.17
48.17
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
21.78
19.02
16.80
15.48
PBIDTM%
23.99
21.61
18.50
17.56
PBDTM%
22.96
20.66
16.66
16.70
PBTM%
17.20
14.88
11.89
11.36
PATM%
12.82
10.40
8.35
7.90
 
Notes
Notes
Notes
Notes

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.